Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Dunash ben Labrat
The field of drug discovery is constantly seeking innovative approaches to overcome the challenges associated with developing new therapeutics. Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize the drug discovery process. This abstract provides an overview of the resources, methods, and applications of AI in drug discovery. It highlights the role of AI in addressing the complexities and costs of drug development, while emphasizing its potential to accelerate the identification of novel therapeutic targets and optimize lead compounds. The abstract also discusses the use of AI in clinical trial optimization and drug repurposing, demonstrating its versatility in different stages of the drug discovery pipeline. Additionally, it explores the challenges and limitations of AI, such as ethical considerations and regulatory hurdles, and offers insights into future directions and implications. Overall, this abstract highlights the significant impact of AI in drug discovery and its potential to transform the pharmaceutical industry by improving efficiency, accuracy, and success rates in the development of new treatments.